» Articles » PMID: 24136375

A GCH1 Haplotype Confers Sex-specific Susceptibility to Pain Crises and Altered Endothelial Function in Adults with Sickle Cell Anemia

Abstract

GTP cyclohydrolase (GCH1) is rate limiting for tetrahydrobiopterin (BH4) synthesis, where BH4 is a cofactor for nitric oxide (NO) synthases and aromatic hydroxylases. GCH1 polymorphisms are implicated in the pathophysiology of pain, but have not been investigated in African populations. We examined GCH1 and pain in sickle cell anemia where GCH1 rs8007267 was a risk factor for pain crises in discovery (n = 228; odds ratio [OR] 2.26; P = 0.009) and replication (n = 513; OR 2.23; P = 0.004) cohorts. In vitro, cells from sickle cell anemia subjects homozygous for the risk allele produced higher BH4. In vivo physiological studies of traits likely to be modulated by GCH1 showed rs8007267 is associated with altered endothelial dependent blood flow in females with SCA (8.42% of variation; P = 0.002). The GCH1 pain association is attributable to an African haplotype with where its sickle cell anemia pain association is limited to females (OR 2.69; 95% CI 1.21-5.94; P = 0.01) and has the opposite directional association described in Europeans independent of global admixture. The presence of a GCH1 haplotype with high BH4 in populations of African ancestry could explain the association of rs8007267 with sickle cell anemia pain crises. The vascular effects of GCH1 and BH4 may also have broader implications for cardiovascular disease in populations of African ancestry.

Citing Articles

Genetic contributions to pain modulation in sickle cell: A focus on single nucleotide polymorphisms.

Hamilton K, McGill L, Campbell C, Lanzkron S, Carroll C, Latremoliere A Gene Rep. 2024; 36.

PMID: 39219841 PMC: 11361162. DOI: 10.1016/j.genrep.2024.101983.


Differential clinical characteristics across traditional Chinese medicine (TCM) Syndromes in patients with sickle cell disease.

Wang Y, Wang D, Pucka A, OBrien A, Harte S, Harris R Front Pain Res (Lausanne). 2024; 4:1233293.

PMID: 38249565 PMC: 10796810. DOI: 10.3389/fpain.2023.1233293.


Genetic Variation and Sickle Cell Disease Severity: A Systematic Review and Meta-Analysis.

Kirkham J, Estepp J, Weiss M, Rashkin S JAMA Netw Open. 2023; 6(10):e2337484.

PMID: 37851445 PMC: 10585422. DOI: 10.1001/jamanetworkopen.2023.37484.


Single nucleotide polymorphisms and sickle cell disease-related pain: a systematic review.

Gehling G, Powell-Roach K, Wilkie D, Dungan J Front Pain Res (Lausanne). 2023; 4:1223309.

PMID: 37781219 PMC: 10538969. DOI: 10.3389/fpain.2023.1223309.


Peripheralized sepiapterin reductase inhibition as a safe analgesic therapy.

Cronin S, Andrews N, Latremoliere A Front Pharmacol. 2023; 14:1173599.

PMID: 37251335 PMC: 10213231. DOI: 10.3389/fphar.2023.1173599.


References
1.
Zennadi R, Moeller B, Whalen E, Batchvarova M, Xu K, Shan S . Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood. 2007; 110(7):2708-17. PMC: 1988948. DOI: 10.1182/blood-2006-11-056101. View

2.
Lazarev M, Lamb J, Barmada M, Dai F, Anderson M, Max M . Does the pain-protective GTP cyclohydrolase haplotype significantly alter the pattern or severity of pain in humans with chronic pancreatitis?. Mol Pain. 2008; 4:58. PMC: 2626574. DOI: 10.1186/1744-8069-4-58. View

3.
Mogil J, Sorge R, LaCroix-Fralish M, Smith S, Fortin A, Sotocinal S . Pain sensitivity and vasopressin analgesia are mediated by a gene-sex-environment interaction. Nat Neurosci. 2011; 14(12):1569-73. PMC: 3225498. DOI: 10.1038/nn.2941. View

4.
Kellogg Jr D, Zhao J, Coey U, Green J . Acetylcholine-induced vasodilation is mediated by nitric oxide and prostaglandins in human skin. J Appl Physiol (1985). 2005; 98(2):629-32. DOI: 10.1152/japplphysiol.00728.2004. View

5.
CHARACHE S, Terrin M, Moore R, Dover G, Barton F, Eckert S . Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995; 332(20):1317-22. DOI: 10.1056/NEJM199505183322001. View